190965-42-5

Basic information

• Product Name: 3-PROPOXYBENZOIC ACID
• Synonyms: 3-PROPOXYBENZOIC ACID;AKOS BBB/288;ARONIS010407;ChemDiv2_002184;MLS000043924;SMR000021135;ZERO/001805
• CAS NO: 190965-42-5
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180.2
• Mol File: 190965-42-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 75.5 °C
• Boiling Point: 118-123 °C(Press: 0.1 Torr)
• Appearance: /
• Density: 1.133±0.06 g/cm3(Predicted)
• PKA: pK1:4.20 (20°C)
• CAS DataBase Reference: 3-PROPOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PROPOXYBENZOIC ACID(190965-42-5)
• EPA Substance Registry System: 3-PROPOXYBENZOIC ACID(190965-42-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 190965-42-5(Hazardous Substances Data)

Usage

General Description

3-Propoxybenzoic acid is an organic chemical compound with the molecular formula C10H12O3. It is a carboxylic acid that contains a benzene ring with a propoxy group attached to the para position. 3-PROPOXYBENZOIC ACID is often used in organic synthesis and pharmaceutical research as a building block for the preparation of various derivatives and analogs. It has also been studied for its potential anti-inflammatory and analgesic properties. 3-Propoxybenzoic acid may also have applications in the development of new materials and as a precursor in the production of specialty chemicals.

Upstream product

• 7781-98-8 ethyl-3-hydroxybenzoate 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 148433-10-7 methyl 3-propoxybenzoate 

Downstream Products

• 83230-74-4 3-propoxy-benzoyl chloride 
• 1054632-48-2 C₆₂H₈₅NO₁₅Si₂ 
• 759393-68-5 3-propoxy-benzoic acid-(2-diethylamino-ethyl ester) 

Relevant articles and documents

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS

The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed.